Co-Clinical PDX Models in the Design and Development of Clinical Trials
Developing co-clinical PDX models from patients enrolled and treated in a clinical trial represents a next-generation approach to optimizing oncology drug development by affording a more profound and timely understanding of tumor response to experimental agents while helping to advance clinical development plans.
A clinical trial strategy that incorporates Champions TumorGraft PDX models established from trial participants creates surrogate patients with validated clinical outcomes data. Co-clinical PDX models, or PDX models established within the context of a clinical trial, represent an invaluable, almost limitless resource for understanding the genomic differences between responders and non-responders, identifying mechanisms of resistance, and for current and future hypothesis testing, enabling novel insights linking benefits to therapies. All done at a fraction of the cost of a clinical trial designed to test those variables in a new cohort of patients.
The Champions Oncology Clinical Operation Team is uniquely positioned to not only provide expert review and input to clinical trial protocols, consents and other ancillary documents but also able to provide the global infrastructure and extensive logistics necessary to acquire, collect and transport tissue from clinical trial patients for co-clinical PDX model development. From documentation for IRB submission and site training to sample collection/ transportation and monthly reporting, Champions Oncology’s clinical operations capabilities and quality measures ensures the development and utilization of PDX from patients enrolling in clinical trials is seamless and effortless.
Contact us to learn more about optimizing the oncology drug development process by working with Champions Oncology to incorporate co-clinical PDX model development in clinical trial protocols.